Latest Competition News

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

RLF AgTech Ltd has secured $4.5 million through a discounted share placement to support its strategic growth initiatives following a robust 74% revenue increase in FY2025. The company is advancing its Australian relaunch, expanding manufacturing, and entering new Asian markets.

RLF AgTech has secured a national supply agreement with Nutrien Ag Solutions, granting access to over 700 rural retail outlets across Australia. This partnership aims to boost RLF’s domestic presence and support sustainable farming practices.

Carbonxt Group Limited has announced a fully underwritten non-renounceable entitlement offer of Loyalty Options to eligible shareholders, aiming to raise approximately $697,772 to support its new Activated Carbon manufacturing facility in Kentucky. The offer provides shareholders with one Loyalty Option for every six shares held, exercisable at $0.07 within three years.

NOVONIX Limited reports progress scaling its Chattanooga synthetic graphite plant, secures major funding, and benefits from U.S. tariffs on Chinese imports, while narrowing its half-year loss.

LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.

Accent Group reported a modest 0.8% increase in FY2025 total sales to $1.62 billion, while profits dipped slightly. The company is advancing its store expansion and brand portfolio, targeting strong EBIT growth in FY26 despite startup costs.

Accent Group Limited reported a modest revenue increase but a 3.1% decline in net profit for FY25 amid a tough retail environment. The company announced a strategic partnership with Frasers Group to launch Sports Direct in Australia and New Zealand, signaling a new growth avenue.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Helia Group Limited delivered robust half-year results for 2025, reporting a statutory net profit after tax of $134 million and a significant 28% increase in gross written premiums. The company strengthened its capital position while navigating a shifting mortgage insurance landscape.

Helia Group reports a robust 38% rise in statutory net profit for the first half of 2025, alongside a special dividend declaration, while navigating looming challenges from government policy shifts and lender contract changes.

Cobram Estate Olives Limited has reported record financial results for FY2025, driven by strong sales growth in Australia and a doubling of branded sales in the USA. The company is shifting its capital expenditure focus to expand its Californian operations while maintaining sustainable growth in Australia.